Diabetes, Heart and Cardiovascular Diseases News Chronicle.  Diabetes, Cardiovascular and Heart Diseases
 Article 229
    Published on August 19, 2017

Risk of type 2 diabetes, high blood pressure and cardiovascular diseases with phthalate chemicals

A study done by the Australian researchers from the South Australian Health and Medical Research Institute (SAHMRI) and the University of Adelaide linked the development of diseases such as type 2 diabetes (T2D) or high blood sugar or glucose levels, cardiovascular disease and high blood pressure or hypertension in male individuals with phthalates, a dangerous chemical toxin used for making food packaging and plastics. Plastic manufacturers use phthalates chemicals to improves the flexibility of plastics.

Researchers had conducted tests among 1,500 male adult individuals. The urine samples show a presence of phthalates in 99.6 percent of the participants, who were aged 35 years or more. Possible reasons for the presence of high levels of phthalates as per earlier studies are

  • Western diet and age
  • Consuming more processed food and fewer vegetable and fruit

They found higher sugar or glucose levels, high blood pressure or hypertension and cardiovascular diseases among participants who are with higher total phthalate levels. The association between the development of diseases with the presence of phthalates is independent of other health factors such as lifestyle, obesity or overweight, alcohol consumption and smoking. But the researchers unable to give reasons for the development of chronic diseases with the presence of phthalates. Even though researchers found evidence to the development of diseases with the presence of phthalates among men, they believe similar results among women too.

Risk of type 2 diabetes blood pressure cardiovascular diseases with phthalates chemicals in plastics.

Senior author of the study was Zumin Shi, an associate professor, Adelaide Medical School, the University of Adelaide, Australia and Freemasons Foundation Centre for Men's Health. The study findings were published July 2017 in the journal Environmental Research. Title of the article was "The association between total phthalate concentration and non-communicable diseases and chronic inflammation in South Australian urban dwelling men."

Post a message on social media and mail to your friend and doctor to resolve your health condition. Article address TO LINK to your social media is (copy and paste the code below) :

Articles similar to this topic

1. Study Finds Risk Of Cardiovascular Diseases with The Combination Of Noise And Urban Traffic Air Pollution
2. Nanoparticles In Air Pollution Lead To Stroke, Cardiovascular And Heart Diseases
3. Increased risk of cardiovascular diseases with pneumonia or sepsis infection
4. Risk of heart disease in women can be predicted with race and weight gain
6. Risk Of High blood pressure Hypertension Being Short
7. A new wearable smart device to measure sugar levels, stress and inflammation from sweat
8. Heartisans Wearable Smartwatch Device That Can Alert Heart Attacks



Urocortin 2 (Ucn2) gene transfer therapy improves insulin sensitivity and reduces blood sugar or glucose levels (HbA1c)

A study done on mice models by the researchers shows an increase in the insulin sensitivity (means reduced blood sugar or glucose levels or HbA1c) with Urocortin 2 (Ucn2) gene transfer therapy, which activates a receptor called CRF in the insulin resistant cells. The current study by the researchers on mice models which are lacking with Ucn2 gene and fed with an unhealthy diet show lower fat accumulation, increased lean muscle tissue and increased insulin sensitivity. Other benefits include weight loss, reduction in liver fat, blood sugar or glucose control (means better HbA1c levels) and better heart function. This therapy was designed by Dr. Kirk H Hammond, MD, Professor of Medicine, the University of California (UCSD) and also co-founder of Renova Therapeutics, a biotechnology company which is going to deliver this gene therapy to the patients.

Urocortin 2 Ucn2 gene transfer therapy improves insulin sensitivity in blood sugar glucose levels HbA1c.

Earlier research done by Dr. Kirk H Hammond resulted in the development of Urocortin 3 (Ucn3) gene transfer therapy intended to improve heart function in heart failure patients. This therapy is similar to the current Urocortin 2 (Ucn2) gene therapy. Now the researchers are planning to conduct clinical trials for Urocortin 2 (Ucn2) gene therapy with type 2 diabetes (T2D) patients. The study findings were published in the National Center for Biotechnology Information and also presented in the American Heart Association's Scientific Sessions. Title of the article was "One-time injection of AAV8 encoding urocortin 2 provides long-term resolution of insulin resistance."

Post a message on social media and mail to your friend and doctor to resolve your health condition. Article address TO LINK to your social media is (copy and paste the code below) :

Articles similar to this topic

1. Single dose of glucagon receptor antibody found to be as effective in reducing insulin need
2. Prevention of heart diseases with an extra injection of insulin after meals in type 1 diabetes patients
3. Canagliflozin (Invokana) shown to improve metabolic function, HbA1c And Leptin Hormone
4. Galvus (Vildagliptin) Gliptins Drug Helps In Improving HbA1c Levels
6. New Type 2 Diabetes Drug That Works Efficiently In Reducing Blood Sugar Levels
7. Inflammation hormones risk with glucose-gobbling immune cells hidden in plaque of coronary artery disease CAD patients
8. Diabetes High Blood Sugar Or Glucose Levels Can Protect Gliomas Brain Tumour or Tumor And Brain Cancer




Site maps

Site map 1   Site map 2   Site map 3   Site map 4

The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. Published article is not a medical advice by the OWNER of "Diabetes News Chronicle" website or by the AUTHOR of the article.

Published by Jammi Vasista, Chennai, India.
Email Jammi[no-space]Vasista1991[at]gmail[dot]com
Phone 91-944-578-3182.
Address Diabetes News Chronicle, No 40, Kaveri Street, Rajaji Nagar, Villivakkam, Chennai, India. Pin : 600049.